Related Experiment Video
Updated: Feb 5, 2026

In Vitro Thrombosis Test for Ventricular Assist Devices
Published on: March 21, 2025
Antithrombotic therapy in ventricular assist device (VAD) management: From ancient beliefs to updated evidence. A
Nuccia Morici1,2, Marisa Varrenti3, Dario Brunelli1,4
1Intensive Cardiac Care Unit and De Gasperis Cardio Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Insights
Antiplatelet drugs are crucial for managing ventricular assist device (VAD) thrombosis. Current strategies face challenges with bleeding and clotting, necessitating optimized antithrombotic regimens for VAD patients.
Area of Science:
- Cardiovascular Medicine
- Hematology
- Biomedical Engineering
Background:
- Platelets are central to ventricular assist device (VAD) thrombosis.
- Antiplatelet therapy is vital for acute and long-term VAD management.
- Aspirin is the standard lifelong treatment post-VAD implantation.
Purpose of the Study:
- To review evidence on antithrombotic strategies for VAD patients.
- To explore pathophysiologic mechanisms of bleeding and thrombosis in VADs.
- To identify optimal pharmacological management for VAD-associated thrombotic and bleeding events.
Main Methods:
- Review of randomized clinical trials.
- Analysis of observational studies.
- Focus on pathophysiologic mechanisms of VAD thrombosis and bleeding.
Main Results:
- Bleeding and thrombotic events remain frequent in VAD patients.
- Dual antiplatelet therapy increases bleeding risk.
- Uniform strategies for VAD antithrombotic management are lacking.
Conclusions:
- Optimizing antithrombotic regimens is critical for VAD patient outcomes.
- Further research is needed to establish standardized VAD management protocols.
- Balancing antithrombotic efficacy and bleeding risk remains a key challenge.
Abstract:
Platelets play a key role in the pathogenesis of ventricular assist device (VAD) thrombosis; therefore, antiplatelet drugs are essential, both in the acute phase and in the long-term follow-up in VAD management. Aspirin is the most used agent and still remains the first-choice drug for lifelong administration after VAD implantation. Anticoagulant drugs are usually recommended, but with a wide range of efficacy targets. Dual antiplatelet therapy, targeting more than one pathway of platelet activation, has been used for patients developing a thrombotic event, despite an increased risk of bleeding complications. Although different strategies have been attempted, bleeding and thrombotic events remain frequent and there are no uniform strategies adopted for pharmacological management in the short and mid- or long-term follow up. The aim of this article is to provide an overview of the evidence from randomized clinical trials and observational studies with a focus on the pathophysiologic mechanisms underlying bleeding and thrombosis in VAD patients and the best antithrombotic regimens available.
Related Concept Videos
The Evidence for Evolution
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Gene Therapy
Group Therapy

